新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 癌症研究 » PLoS Med:用PDE5抑制剂治疗勃起功能障碍不太可能会增加患皮肤癌几率

PLoS Med:用PDE5抑制剂治疗勃起功能障碍不太可能会增加患皮肤癌几率

来源:生物谷 2016-06-17 09:51

2016年6月17日讯/生物谷BIOON/根据一篇发表在《PLOS Medicine》杂志上的文章,有三种药物可治疗勃起功能障碍,但它们不太可能会增加患恶性黑色素瘤的风险。

来自伦敦卫生与热带医学学院的研究人员发现,与对照组相比,男性服用西地那非、他达拉非,伐地那非等药物只会轻微增加病人患恶性黑色素瘤的风险,这似乎可以解释为是由于晒太阳太多引起的。

众所周知,这三种已知药物可抑制5型磷酸二酯酶(PDE5),减少这种酶的表达与增加体外黑色素瘤细胞的生长相关。流行病学研究因此着重检测男性长期使用治疗勃起功能障碍的PDE5抑制剂时增加黑色素瘤风险的可能性。

先前的研究对男性在服用其中一种药物时可能增加患黑素瘤的风险的结论相互矛盾,因此Anthony Matthews和他的同事们使用临床研究实践数据库对英国男性进行了一项大型研究。

本研究将使用PDE5抑制剂的145,104名男性与560,933名未服用药物的男性进行对照。研究人员观察到患皮肤黑素瘤的风险有轻微的增加(调整危害比为1.14,95%可信区间1.01 -1.29,p = 0.04)。然而,基底细胞癌和日光性角化病的风险也有相应的增加,众所周知日光性角化病和阳光照射有关。然而结直肠癌没有增加的风险,这与日晒无关。

此外,使用PDE5抑制剂的男性组患日光性角化病的风险较高,即便在他们首次服药之前,这表明他们的平均日照程度的比对照组较高。

这项研究的作者Krishnan Bhaskaran说,“我们所有的观察结果指向服用PDE5抑制剂的男性会轻微增加患黑色素瘤的风险,主要是因为他们被阳光照射的缘故,而不是药物本身的副作用。”(生物谷Bioon.com)

本文系生物谷原创编译整理,欢迎转载!点击 获取授权 。更多资讯请下载生物谷APP.

 

Phosphodiesterase Type 5 Inhibitors and Risk of Malignant Melanoma: Matched Cohort Study Using Primary Care Data from the UK Clinical Practice Research Datalink

Anthony Matthews, Sinéad M. Langan, Ian J. Douglas, Liam Smeeth, Krishnan Bhaskaran

 

We conducted a matched cohort study using primary care data from the UK Clinical Practice Research Datalink. All men initiating a PDE5 inhibitor and with no prior cancer diagnosis were identified and matched on age, diabetes status, and general practice to up to four unexposed controls. Ever use of a PDE5 inhibitor and time-updated cumulative number of PDE5 inhibitor prescriptions were investigated as exposures, and the primary outcome was malignant melanoma. Basal cell carcinoma, solar keratosis, and colorectal cancer were investigated as negative control outcomes to exclude bias. Hazard ratios (HRs) were estimated from Cox models stratified by matched set and adjusted for potential confounders. 145,104 men with ≥1 PDE5 inhibitor prescription, and 560,933 unexposed matched controls were included. In total, 1,315 incident malignant melanoma diagnoses were observed during 3.44 million person-years of follow-up (mean 4.9 y per person). After adjusting for potential confounders, there was weak evidence of a small positive association between PDE5 inhibitor use and melanoma risk (HR = 1.14, 95% CI 1.01–1.29, p = 0.04). A similar increase in risk was seen for the two negative control outcomes related to sun exposure (HR = 1.15, 95% CI 1.11–1.19, p < 0.001, for basal cell carcinoma; HR = 1.21, 95% CI 1.17–1.25, p < 0.001, for solar keratosis), but there was no increased risk for colorectal cancer (HR = 0.91, 95% CI 0.85–0.98, p = 0.01). There was no evidence that risk increased with number of prescriptions received (p-trend = 0.83). In a post hoc analysis, there was strong evidence that solar keratosis was associated with future PDE5 inhibitor use (odds ratio = 1.28, 95% CI 1.23–1.34, p < 0.001), suggesting that men with higher sun exposure were more likely to become PDE5 inhibitor users. However, a limitation of our study was that we did not have individual-level data on sun exposure, so we could not directly control for this in the primary analysis.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库